Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,083,134
  • Shares Outstanding, K 223,100
  • Annual Sales, $ 3,551 M
  • Annual Income, $ 443,300 K
  • 36-Month Beta 1.02
  • Price/Sales 7.35
  • Price/Cash Flow 14.56
  • Price/Book 2.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.63
  • Number of Estimates 7
  • High Estimate 1.78
  • Low Estimate 1.50
  • Prior Year 1.28
  • Growth Rate Est. (year over year) +27.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
110.95 +0.73%
on 12/14/18
129.36 -13.60%
on 12/04/18
-4.35 (-3.74%)
since 11/14/18
3-Month
109.74 +1.85%
on 10/29/18
140.77 -20.60%
on 09/28/18
-6.43 (-5.44%)
since 09/14/18
52-Week
102.10 +9.47%
on 04/20/18
140.77 -20.60%
on 09/28/18
-1.32 (-1.17%)
since 12/14/17

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

IBB : 102.85 (-1.00%)
GILD : 66.22 (-1.68%)
REGN : 380.70 (+0.58%)
ALXN : 110.66 (-1.57%)
BIIB : 316.88 (-1.02%)
4 Biotech Stocks Investors Can Add to Their Portfolio in 2019

Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.

GILD : 66.22 (-1.68%)
REGN : 380.70 (+0.58%)
BIIB : 316.88 (-1.02%)
ALXN : 110.66 (-1.57%)
Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher

Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ABEO : 7.50 (-1.06%)
ALXN : 110.66 (-1.57%)
Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher

Clovis Oncology (CLVS) shares rose nearly 7% in the last trading session, amid huge volumes.

CLVS : 19.94 (-7.81%)
ALXN : 110.66 (-1.57%)
5 Top Drug/Biotech Merger & Acquisition Targets for 2019

Here are five stocks that are attractive and most likely to be takeout targets in 2019.

CELG : 68.58 (-1.66%)
BMRN : 93.14 (-0.80%)
VRTX : 170.59 (-1.63%)
ALNY : 73.87 (-2.37%)
INCY : 67.05 (-0.36%)
SNY : 44.18 (-1.58%)
ALXN : 110.66 (-1.57%)
Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis

Biogen (BIIB) obtains a license to develop and commercialize BIIB067 from Ionis Pharmaceuticals. The candidate is being developed for treatment of ALS with SOD1 mutations.

IONS : 53.32 (-0.28%)
GILD : 66.22 (-1.68%)
BIIB : 316.88 (-1.02%)
ALXN : 110.66 (-1.57%)
Inovio (INO) to Receive Milestone Payment From AstraZeneca

Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.

AZN : 39.03 (-0.54%)
INO : 5.04 (-1.18%)
VNDA : 26.54 (+1.49%)
ALXN : 110.66 (-1.57%)
UNITY (UBX) Soars: Stock Adds 5.1% in Session

UNITY (UBX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

UBX : 16.31 (-1.33%)
ALXN : 110.66 (-1.57%)
Should You Get Rid of Acadia Healthcare (ACHC) Now?

Acadia Healthcare (ACHC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

ACHC : 30.07 (-3.19%)
ALXN : 110.66 (-1.57%)
Amgen's BiTE Immunotherapies Show Promise in Early Studies

Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA

GILD : 66.22 (-1.68%)
AMGN : 193.44 (-2.07%)
VNDA : 26.54 (+1.49%)
ALXN : 110.66 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ALXN with:

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

2nd Resistance Point 120.27
1st Resistance Point 116.35
Last Price 110.66
1st Support Level 110.42
2nd Support Level 108.41

See More

52-Week High 140.77
Fibonacci 61.8% 126.00
Fibonacci 50% 121.43
Fibonacci 38.2% 116.87
Last Price 110.66
52-Week Low 102.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar